scholarly journals Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Yanlan Xu ◽  
Xinyu Yang ◽  
Hua Bian ◽  
Mingfeng Xia
Keyword(s):  
Liver Disease ◽  
Liver Injury ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Receptor Expression ◽  
Metabolic Dysfunction ◽  
Drug Induced ◽  
Hypoxic Injury ◽  
Definition Of ◽  
The Relationship

AbstractThe coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). At present, the COVID-19 has been prevalent worldwide for more than a year and caused more than four million deaths. Liver injury was frequently observed in patients with COVID-19. Recently, a new definition of metabolic dysfunction associated fatty liver disease (MAFLD) was proposed by a panel of international experts, and the relationship between MAFLD and COVID-19 has been actively investigated. Several previous studies indicated that the patients with MAFLD had a higher prevalence of COVID-19 and a tendency to develop severe type of respiratory infection, and others indicated that liver injury would be exacerbated in the patients with MAFLD once infected with COVID-19. The mechanism underlying the relationship between MAFLD and COVID-19 infection has not been thoroughly investigated, and recent studies indicated that multifactorial mechanisms, such as altered host angiotensin converting enzyme 2 (ACE2) receptor expression, direct viral attack, disruption of cholangiocyte function, systemic inflammatory reaction, drug-induced liver injury, hepatic ischemic and hypoxic injury, and MAFLD-related glucose and lipid metabolic disorders, might jointly contribute to both of the adverse hepatic and respiratory outcomes. In this review, we discussed the relationship between MAFLD and COVID-19 based on current available literature, and summarized the recommendations for clinical management of MAFLD patients during the pandemic of COVID-19.

scholarly journals Drug Induced Liver Injury (Dili) and Non Alcoholic Fatty Liver Disease (Nafld)

2020 ◽  
Vol 2 (4) ◽  
Author(s):  
Goran Bokan ◽  
Nikola Malešević ◽  
Anna Licata ◽  
Zoran Mavija
Keyword(s):  
Liver Disease ◽  
Liver Injury ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Review Article ◽  
Drug Induced ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Drug Induced Liver Injury ◽  
Definition Of

This review article includes a review of the latest literature searched on PubMed in the field of hepatotoxicity caused by drugs that have a wide daily application. The concept of the review article consists of several parts dealing with the definition of drugs induced liver injury - DILI, diagnostic challenges related to it, and the clinical spectrum of liver disease, with an emphasis on the development of nonalcoholic fatty liver disease - NAFLD and review of drugs involved in formation of NAFLD.

scholarly journals Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury

2021 ◽  
Vol Volume 14 ◽  
pp. 3667-3671
Author(s):  
Yi-Hui Liu ◽  
Yan Guo ◽  
Hong Xu ◽  
Hui Feng ◽  
Dong-Ya Chen
Keyword(s):  
Liver Disease ◽  
Liver Injury ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals Clinical Validity of the diagnostic criteria for metabolic-associated fatty liver disease: a real-world experience

2020 ◽  
Author(s):  
Yasser Fouad ◽  
Zeinab Saad ◽  
Ehab Abdel Raheem ◽  
Yasser Abel gany ◽  
Hend Moness ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Multivariable Analysis ◽  
Metabolic Dysfunction ◽  
Alcoholic Fatty Liver ◽  
Clinical Criteria ◽  
Nafld Fibrosis Score ◽  
Definition Of ◽  
The Impact

Background and Aims: To eliminate the anti-definition of non-alcoholic fatty liver disease (NAFLD), positive clinical criteria for metabolic associated fatty liver disease are recently proposed. In this study, we examine the validation and utilization of these criteria. METHODS: Two cohorts of 316 consecutive patients were recruited, including 242 patients previously diagnosed to have NAFLD and 74 patients with concomitant NAFLD and chronic hepatitis C (CHC) The validity of the proposed criteria for MAFLD, namely presence of hepatic steatosis with one of three criteria, overweight/obesity, diabetes or evidence of metabolic dysregulation was assessed. Fibrosis was assessed using, fibrosis-4 (FIB-4) and NAFLD fibrosis score (NFS). The impact of MAFLD on the clinical outcomes in CHC patients was also investigated. Results: The clinical criteria captured 240 patients (99.2%). 215 (88.8%) met either overweight or diabetes and 25 (10.3%) met the presence of 2 criteria of metabolic dysfunction. In patients, with dual etiologies, in the multivariable analysis adjusting for age, sex, BMI, ALT, AST and diabetes, the presence of MAFLD were significantly associated with increase high FIB-4 score of fibrosis (Odds ratio [95% confidence interval], 3.77 [1.49-9.48], P < 0.005) when compared to those with MAFLD only. CONCLUSION: The proposed criteria for diagnosis of MAFLD is well validated and easily applicable to the entire spectrum of disease including non-obese subjects. Patients with lean MAFLD have favorable metabolic and fibrosis characteristics compared to their obese counterpart, while patients with concomitant MAFLD and CHC had severe metabolic and fibrosis characteristics compared to patients with MAFLD alone.

scholarly journals Astaxanthin Prevents Alcoholic Fatty Liver Disease by Modulating Mouse Gut Microbiota

Nutrients ◽  
2018 ◽  
Vol 10 (9) ◽  
pp. 1298 ◽  
Author(s):  
Huilin Liu ◽  
Meihong Liu ◽  
Xueqi Fu ◽  
Ziqi Zhang ◽  
Lingyu Zhu ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Injury ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Serum Markers ◽  
Alcoholic Fatty Liver ◽  
Ethanol Group ◽  
The Relationship ◽  
Alcoholic Fatty Liver Disease

The development and progression of alcoholic fatty liver disease (AFLD) is influenced by the intestinal microbiota. Astaxanthin, a type of oxygenated carotenoid with strong antioxidant and anti-inflammatory properties, has been proven to relieve liver injury. However, the relationship between the gut microbiota regulation effect of astaxanthin and AFLD improvement remains unclear. The effects of astaxanthin on the AFLD phenotype, overall structure, and composition of gut microbiota were assessed in ethanol-fed C57BL/6J mice. The results showed that astaxanthin treatment significantly relieves inflammation and decreases excessive lipid accumulation and serum markers of liver injury. Furthermore, astaxanthin was shown to significantly decrease species from the phyla Bacteroidetes and Proteobacteria and the genera Butyricimonas, Bilophila, and Parabacteroides, as well as increase species from Verrucomicrobia and Akkermansia compared with the Et (ethanol)group. Thirteen phylotypes related to inflammation as well as correlated with metabolic parameters were significantly altered by ethanol, and then notably reversed by astaxanthin. Additionally, astaxanthin altered 18 and 128 KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways involved in lipid metabolism and xenobiotic biodegradation and metabolism at levels 2 and 3, respectively. These findings suggest that Aakkermansia may be a potential target for the astaxanthin-induced alleviation of AFLD and may be a potential treatment for bacterial disorders induced by AFLD.

Sign in / Sign up

Export Citation Format

Share Document